Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

IDYA IDEAYA Biosciences Inc

41,00

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:09:38

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more IDEAYA Biosciences Charts.

IDEAYA Biosciences (NASDAQ:IDYA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more IDEAYA Biosciences Charts.

News IDEAYA Biosciences Inc

Form 8-K - Current report
Dienstag 7 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Dienstag 7 Mai 2024 (2 Wochen vor) • PR Newswire (US)

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
Mittwoch 1 Mai 2024 (3 Wochen vor) • PR Newswire (US)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Freitag 26 April 2024 (4 Wochen vor) • PR Newswire (US)

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Mittwoch 24 April 2024 (4 Wochen vor) • PR Newswire (US)

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Montag 22 April 2024 (4 Wochen vor) • PR Newswire (US)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Freitag 5 April 2024 (2 Monate vor) • PR Newswire (US)

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
Montag 1 April 2024 (2 Monate vor) • PR Newswire (US)

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
Dienstag 12 März 2024 (2 Monate vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 4 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 4 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 4 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere IDEAYA Biosciences Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen